Price movement over the last 24 hours
Alcon AG vs Delta Air Lines, Inc. — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Delta Air Lines, Inc. trades at $87.27 (market cap $58.23B). The key difference: Delta Air Lines, Inc. is the larger of the two by market cap, and Delta Air Lines, Inc. pays the higher dividend (0.88%). Which is the better fit depends on your goals.
| ALC | DAL | |
|---|---|---|
Market Cap | $32.69B | $58.23B |
Sector | Health | Industrials |
52-Week High | $92.22 | $93.66 |
52-Week Low | $62.02 | $50.52 |
Enterprise Value | $36.28B | $73.48B |
Dividend Yield | 0.54% | 0.88% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Delta Air Lines (DAL) trades at $88.63, down 4.44% today, but maintains strong fundamentals with consistent earnings beats and improving cash flow. The stock shows bullish technical signals with moving averages supporting upward momentum, while trading near key support at $88. Analysts remain overwhelmingly positive with 81% buy ratings and a $105.36 consensus target, representing 19% upside potential from current levels.
DAL presents a compelling investment case with attractive valuation multiples (P/E 13.38, P/S 0.92) and robust profitability (ROE 24.99%). However, investors face risks from fuel price volatility, labor cost pressures, and cyclical industry exposure. The upcoming Q2 earnings report on July 10 will be critical for validating current momentum and growth trajectory.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →